Incyte 2013 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer
Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here